Revenue was absent across the ten quarters shown, with operating losses narrowing from -$41.5M in 2024Q2 to -$18.0M in 2026Q2 primarily because R&D expense fell roughly 62 percent over the period.
ALX Oncology Holdings Inc. (ALXO) annual income statement — 8-year revenue, gross profit & net income history
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 |
|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 1.18M | 4.8M | 2.07M |
| Revenue Growth % | - | - | - | - | - | -100% | -75.35% | 132.03% | - |
| Cost of Goods Sold | 150K | 0 | 0 | 0 | 0 | 0 | 1.07M | 4.36M | 1.88M |
| COGS % of Revenue | - | - | - | - | - | - | 90.95% | 90.91% | 90.95% |
| Gross Profit | -150K | 0 | 0 | 0 | 0 | 0 | 107K | 436K | 187K |
| Gross Margin % | - | - | - | - | - | - | 9.05% | 9.09% | 9.05% |
| Gross Profit Growth % | - | - | - | - | - | -100% | -75.46% | 133.16% | - |
| Operating Expenses | 82.82M | 104.02M | 142.47M | 170.28M | 127.44M | 83.56M | 43.77M | 19.62M | 13.87M |
| OpEx % of Revenue | - | - | - | - | - | - | 3703.05% | 409.07% | 671.07% |
| Selling, General & Admin | 21.35M | 23.85M | 26.09M | 28.48M | 29.04M | 23.39M | 14.81M | 3.31M | 2.6M |
| SG&A % of Revenue | - | - | - | - | - | - | 1252.88% | 69.08% | 125.83% |
| Research & Development | 61.85M | 77M | 116.37M | 141.79M | 98.4M | 60.17M | 28.96M | 16.31M | 11.27M |
| R&D % of Revenue | - | - | - | - | - | - | 2450.17% | 339.99% | 545.23% |
| Other Operating Expenses | -388K | 3.17M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -82.97M | -104.02M | -142.47M | -170.28M | -127.44M | -83.56M | -43.66M | -19.18M | -13.68M |
| Operating Margin % | - | - | - | - | - | - | -3693.99% | -399.98% | -662.02% |
| Operating Income Growth % | - | 26.99% | 16.33% | -33.62% | -52.52% | -91.36% | -127.61% | -40.19% | - |
| EBITDA | -82.58M | -103.31M | -141.59M | -169.44M | -127.09M | -83.5M | -43.46M | -18.75M | -13.25M |
| EBITDA Margin % | - | - | - | - | - | - | -3676.9% | -391.03% | -641.17% |
| EBITDA Growth % | 25.5% | 27.03% | 16.43% | -33.32% | -52.2% | -92.14% | -131.74% | -41.51% | - |
| D&A (Non-Cash Add-back) | 387K | 706K | 872K | 836K | 342K | 51K | 202K | 429K | 431K |
| EBIT | -57.75M | -100.09M | -133.12M | -159.24M | -123.18M | -83.47M | -43.66M | -19.19M | -13.69M |
| Net Interest Income | 2.26M | 2.36M | 7.64M | 9.08M | 4.04M | -12.91K | -811K | -21K | 0 |
| Interest Income | 4.64M | 3.96M | 9.37M | 10.65M | 4.28M | 91 | 0 | 0 | 0 |
| Interest Expense | 774K | 1.6M | 1.73M | 1.56M | 238K | 13K | 811K | 21K | 0 |
| Other Income/Expense | 2.39M | 2.33M | 7.62M | 9.47M | 4.02M | 71K | -1.84M | -26K | -2K |
| Pretax Income | -80.57M | -101.69M | -134.85M | -160.81M | -123.42M | -83.48M | -45.5M | -19.21M | -13.69M |
| Pretax Margin % | - | - | - | - | - | - | -3849.32% | -400.52% | -662.12% |
| Income Tax | 0 | 0 | 0 | 0 | 64K | -21K | 241K | 34K | 45K |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | -0.05% | 0.03% | -0.53% | -0.18% | -0.33% |
| Net Income | -80.57M | -101.69M | -134.85M | -160.81M | -123.48M | -83.46M | -45.74M | -19.24M | -13.73M |
| Net Margin % | - | - | - | - | - | - | -3869.71% | -401.23% | -664.3% |
| Net Income Growth % | 25.4% | 24.59% | 16.14% | -30.23% | -47.95% | -82.47% | -137.7% | -40.14% | - |
| Net Income (Continuing) | -80.57M | -101.69M | -134.85M | -160.81M | -123.48M | -83.46M | -45.74M | -19.24M | -13.73M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.57 | -1.90 | -2.58 | -3.74 | -3.03 | -2.07 | -1.28 | -0.88 | -0.79 |
| EPS Growth % | 57.14% | 26.36% | 31.02% | -23.43% | -46.38% | -61.72% | -45.45% | -11.39% | - |
| EPS (Basic) | - | -1.90 | -2.58 | -3.74 | -3.03 | -2.07 | -1.28 | -0.88 | -0.79 |
| Diluted Shares Outstanding | 140.9M | 53.66M | 52.17M | 42.99M | 40.7M | 40.31M | 39.84M | 21.95M | 21.95M |
| Basic Shares Outstanding | 140.9M | 53.66M | 52.17M | 42.99M | 40.7M | 40.31M | 39.84M | 21.95M | 21.95M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
Quick answers to the most common questions about buying ALXO stock.
For fiscal year 2025, ALX Oncology Holdings Inc. (ALXO) reported total revenue of $0.0M. This represents a 100.0% decline compared to $2.1M in 2018.
ALX Oncology Holdings Inc. (ALXO) reported a net loss of $101.7M for the fiscal year ending 2025.
Key Metrics
Top Statement Risk
Persistent operating losses and funding dependence
Metrics are mathematically derived from official filings.
Revenue Absent, Losses Narrowing Steadily
Based on ALXO's reported quarterly figures, revenue was essentially absent across the ten quarters shown, with only minimal COGS of $150K and $220K appearing in two periods, so top-line growth cannot be meaningfully measured.
The absence of reported revenue means the growth-rate column is not interpretable, and no conclusion about revenue durability can be drawn from this data. The more informative trend is the compression of operating losses from roughly -$37.8M in 2024Q1 to -$18.0M in 2026Q2, which reflects a shrinking R&D base rather than any commercial traction. Investors should monitor whether future quarters show a revenue line emerging, as the current profile is that of a pre-commercial development-stage entity.
R&D Reduction Drives Expense Discipline
As reported in the income statement, ALXO's R&D expense fell from $34.7M in 2024Q2 to $13.1M in 2026Q2, roughly a 62 percent reduction, representing the dominant driver of the narrowing operating loss.
R&D accounts for the overwhelming majority of operating expenses, while SG&A has held in a relatively narrow band of about $5M to $8M per quarter. The steady R&D decline may suggest program prioritization or pipeline pruning, though the filings alone do not establish which interpretation is correct. Lower spending improves near-term runway arithmetic, but it also warrants scrutiny of whether clinical momentum is being sacrificed.
Stock Compensation Weighs on Reported Losses
Based on ALXO's reported figures, stock-based compensation ran between $2.1M and $7.3M per quarter, a meaningful share of operating expenses that complicates the read on underlying cash burn.
Because net loss roughly tracks operating loss with little non-operating offset, the reported EPS of -$0.13 to -$0.76 per share is largely an operating story rather than a financing or tax artifact. Stock compensation fluctuates considerably across quarters, which means quarter-to-quarter loss comparisons are partly distorted by equity grant timing. Investors may wish to separate SBC from cash expenses when assessing the true economic burn.
Pre-Revenue Model Carries Dilution Risk
The strongest bear case is that ALXO shows no reported revenue against a cumulative operating loss exceeding $200M over ten quarters, implying continued reliance on external capital markets.
The persistent gap between operating expenses and zero commercial revenue suggests the company remains dependent on equity or debt financing to fund development. Share count growth implied by EPS movements and the scale of historical losses may indicate future dilution pressure. Whether the current R&D reduction reflects disciplined capital allocation or a constrained funding position is a question the reported figures alone cannot resolve, and investors should monitor this closely.